Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Sinking Today

By Keith Speights - May 3, 2021 at 11:48AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors don't like the timing of a potential supply deal with the EU.

What happened

Shares of Novavax (NVAX 11.12%) were sinking 12.8% lower as of 12:05 p.m. EDT on Monday. The decline came after Reuters reported that Novavax plans to begin delivering COVID-19 vaccine NVX-CoV2373 to the European Union near the end of 2021 but most of its commitment of up to 200 million doses won't be shipped until next year.

So what

There's good news and bad news with Reuters' report. The good news is that Novavax appears to be close to finalizing a major supply deal with the EU. The company reached a preliminary agreement with the 27-member economic and political union in December. However, the deal wasn't finalized at that time because Novavax has experienced difficulties sourcing some raw materials.

European Union flag with yellow stars in a circle on a blue background and a gloved hand holding a syringe with a needle in front of the flag

Image source: Getty Images.

What's the bad news? Many investors were hoping that Novavax would see European sales for its COVID-19 vaccine sooner than late 2021 and 2022. With the biotech stock falling today, it's clear that the bad news is outweighing the good news in investors' minds.

At this point, neither Novavax nor the EU has officially commented on the supply agreement. However, European Commission President Ursula von der Leyen hinted in late April that a final deal with Novavax could be on the way. In the announcement of an imminent larger supply agreement with Pfizer and BioNTech, she stated, "We will certainly add other potential vaccines, for example protein-based vaccines have also quite a potential." Novavax's NVX-CoV2373 is a protein-based vaccine.

Now what

The most important thing Novavax needs to do now is to win Emergency Use Authorization (EUA) for NVX-CoV2373. The company has already initiated regulatory filings in the EU, U.K., Canada, Australia, and New Zealand.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$57.15 (11.12%) $5.72

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.